Home » Authors » Karen Young

Articles by Karen Young

Hyseq Raises $15M Privately To Develop Proprietary Drugs

April 10, 2002

InterMune Licenses Rights To Phase II Candidate For Fibrosis

April 9, 2002

InterMune Inc. licensed worldwide rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis a drug candidate that plays right into the company’s field of expertise. (BioWorld Today)

Mojave Presents First Human Data From Antigen Delivery System

April 9, 2002

Mojave Presents First Human Data From Antigen Delivery System

April 9, 2002

InterMune Licenses Rights To Phase II Candidate For Fibrosis

April 9, 2002

InterMune Inc. licensed worldwide rights to develop and commercialize pirfenidone for all fibrotic diseases, including renal, liver and pulmonary fibrosis a drug candidate that plays right into the company’s field of expertise. (BioWorld Today)

Allos Charting Oncology Path, In-Licenses Cancer Product

April 8, 2002

Allos Charting Oncology Path, In-Licenses Cancer Product

April 8, 2002

GenPhar Reveals Platform, Has Partnerships With Army, NIH

April 5, 2002

LifeTime Acquires Cancer Product From Dovetail For Equity Position

April 5, 2002

LifeTime Acquires Cancer Product From Dovetail For Equity Position

April 5, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...